Dupilumab and Prurigo Nodularis-like phenotype in Atopic Dermatitis: our experience of efficacy.
Dupilumab and Prurigo Nodularis-like phenotype in Atopic Dermatitis: our experience of efficacy. J Dermatolog Treat. 2019 Aug 23;:1-8 Authors: Ferrucci S, Tavecchio S, Berti E, Angileri L Abstract Atopic dermatitis (AD) is a common chronic multifactorial dermatosis that can occurs through different clinical phenotypes although all undergone identical pathogenetic mechanisms such as the Prurigo Nodularis (PN)-like phenotype. Here, we described eleven patients with PN-like atopic dermatitis treated with dupilumab, a human monoclonal IgG4 antibody that inhibits interleukine-4 (IL-4) and interleukine-13 (IL-13). Efficacy outcomes were performed at baseline, at first and fourth months from starting treatment. We collected different scores such as NRSi as well as IGA. At the same time, patient subjective benefits were analysed throught DLQI, POEM, HADS scores. Quality of sleep was also recorded by NRSS. All patients showed rapid clinical improvement of cutaneous lesions and no other new lesions were reported during treatment. Reduction of daily itching was referred already after the first month of treatment. These results shows the effectiviness of dupilumab in this clinical setting of AD, supporting this treatment as a valid therapeutic approch in difficult-to-treat-PN-like clinical presentation of AD. PMID: 31442084 [PubMed - as supplied by publisher]
ConclusionsThere was a significant statistical relationship between the concentration of particulate matter (PM2.5 and PM10) and exacerbation of sleep disturbance and itching. PM2.5 showed a stronger relationship with the exacerbation of symptoms compared to PM10.
Background: Atopic dermatitis (AD) is a common chronic, relapsing inflammatory skin disorder associated with increased PDE4 activity, characterized by intense and persistent pruritus which can cause significant impairment in quality of life, including sleep disturbance. Difamilast, a PDE4 inhibitor which is highly selective for PDE4B, is being developed as a 1% ointment for the topical treatment of AD.
Background: Psoriasis, psoriatic arthritis, atopic dermatitis (AD), hidradenitis suppurativa (HS) and chronic urticaria (CU) are associated with sleep disturbances (SD). Validated, disease-specific instruments are needed to assess SD in these populations. This work focuses on the development of the ‘PsO Sleepy-Q’ for psoriasis and ‘PsA Sleepy-Q’ for psoriatic arthritis.
ntilde;as R Abstract The pentapeptides methionine-enkephalin and leucine-enkephalin belong to the opioid family of peptides, and the non-opiate peptide adrenocorticotropin hormone (ACTH) to the melanocortin peptide family. Enkephalins/ACTH are derived from pro-enkephalin, pro-dynorphin or pro-opiomelanocortin precursors and, via opioid and melanocortin receptors, are responsible for many biological activities. Enkephalins exhibit the highest affinity for the δ receptor, followed by the μ and κ receptors, whereas ACTH binds to the five subtypes of melanocortin receptor, and is the only member of the ...
Conclusions:We found altered PSG parameters in children with AD, suggesting that clinicians should consider the diagnosis when affected children undergo PSG. Although our AD cohort was mild, we still determined a need to consider AD when diagnosing PLMD given the presence of elevated total limb movements in children with AD.Citation:Treister AD, Stefek H, Grimaldi D, Rupani N, Zee P, Yob J, Sheldon S, Fishbein AB. Sleep and limb movement characteristics of children with atopic dermatitis coincidentally undergoing clinical polysomnography.J Clin Sleep Med. 2019;15(8):1107–1113.
Rationale: Atopic dermatitis (AD) is a chronic recurrent dermatitis with profound itching, which could be the first manifestation of acute myeloid leukemia (AML). Patient concerns: A 53-year-old Chinese man suffered a 6-month history of systemic symmetrical dermatitis, accompanied with profound itching. The patient was diagnosed as “eczema” in several hospitals, and the effects of antihistamine and topical steroid creams were poor. Nocturnal sleep was seriously affected by aggravating pruritus. Laboratorial examination was compatible with AML-M4. Diagnoses: AML-M4 with AD as first manifestation. Interv...
CONCLUSIONS: Expert consensus recommendations providing practical guidance of clinical relevance to specialists and primary care physicians in Australia have been developed. Dissemination of this guidance and evaluation of its impact on patient outcomes remain to be undertaken. PMID: 31372984 [PubMed - as supplied by publisher]
Condition: Atopic Dermatitis Interventions: Drug: DUPILUMAB; Drug: PLACEBO Sponsors: Sanofi; Regeneron Pharmaceuticals Not yet recruiting
The objective of this study was to identify and evaluate PROMs used in studies of AD and CHE. The aim was to explore the assessment of key symptoms and im pacts, and identify any gaps in the measures in use. A structured review of the PubMed database was conducted to identify PROMs used or developed for use in AD or CHE. The Dermatology Life Quality Index (DLQI), the Pruritus/Itch Numeric Rating Scale (NRS), the Patient-Oriented Eczema Measure (POEM), and the Quality of Life in Hand Eczema Questionnaire (QOLHEQ) were identified and reviewed in detail. With these measures, the AD and CHE symptoms and impacts most commonly e...